LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that the Company has commercially launched Perforomist™ (formoterol fumarate) Inhalation Solution (Perforomist) with its marketing partner, Dey, L.P. (DEY), a subsidiary of Mylan Inc. (NYSE: MYL). Perforomist™ Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).
